Professor Aichun Liu: Stratified Treatment and Novel Drugs Resurrect Hope for Relapsed/Refractory B-Cell Lymphoma at the 2024 CSCO Hematology

Professor Aichun Liu: Stratified Treatment and Novel Drugs Resurrect Hope for Relapsed/Refractory B-Cell Lymphoma at the 2024 CSCO Hematology

2024.03.05
In the era of medical innovation, various targeted and immune drugs are emerging, leading to breakthroughs in lymphoma treatment. From January 26th to 28th, 2024, the "Chinese Society of Clinical Oncology (CSCO) Leukemia Expert Committee, Lymphoma Expert Committee, and Myeloma Preparatory Committee Working Meeting, as well as the 2024 CSCO Hematology and Lymphoma, and Myeloma Disease Academic Conference" was grandly held in the beautiful city of Haikou. At the conference, experts of all ages from both domestic and international arenas engaged in discussions and exchanges on the latest developments and hot topics in lymphoma diagnosis and treatment. "Oncology Frontier - Hematology Frontier" had the privilege to interview Professor Aichun Liu, Director of the Department of Hematology and Lymphoma at Harbin Medical University Cancer Hospital, regarding his perspectives and opinions on the overall treatment strategy for relapsed/refractory B-cell lymphoma, as well as sharing his team's research plans and management experiences in lymphoma.
Professor Hui Wei: Mutual learning and progress, new treatment strategies and future directions in the field of leukemia | 2024 CSCO

Professor Hui Wei: Mutual learning and progress, new treatment strategies and future directions in the field of leukemia | 2024 CSCO

2024.03.05
With the rapid development of targeted therapy and immunotherapy, the field of leukemia treatment has undergone revolutionary changes. At the recently held "Chinese Society of Clinical Oncology (CSCO) Leukemia Expert Committee, Lymphoma Expert Committee, and Myeloma Preparatory Committee Working Meeting and the 2024 CSCO Hematology, Lymphoma, and Myeloma Disease Academic Conference," domestic and international experts, both senior and junior, actively exchanged ideas and engaged in lively discussions on the latest developments and hot topics in leukemia diagnosis and treatment. During the conference, Oncology Frontier - Hematology Frontier specially invited Professor Hui Wei, one of the co-chairs of the leukemia youth session at this conference and director of the Leukemia Diagnosis and Treatment Center of the Institute of Hematology, Chinese Academy of Medical Sciences (Chinese Academy of Medical Sciences Blood Disease Hospital), to introduce the highlights of the leukemia field at this conference. Professor Wei also provided insights into the future treatment directions for ETP Acute Leukemia (ETP-ALL) and analyzed related challenges in CAR-T cell therapy.
Professor DeHui Zou : Progress and Considerations in CAR-T Therapy for Diffuse Large B-Cell Lymphoma | 2024 CSCO Hematology Academic Conference

Professor DeHui Zou : Progress and Considerations in CAR-T Therapy for Diffuse Large B-Cell Lymphoma | 2024 CSCO Hematology Academic Conference

2024.03.05
With unceasing exploration, the grand event took place as scheduled. From January 26 to 28, 2024, the "Chinese Society of Clinical Oncology (CSCO) Leukemia Committee, Lymphoma Committee, and Myeloma Committee Work Meeting and the 2024 CSCO Academic Conference on Hematology, Lymphoma, and Myeloma" was grandly held in the beautiful city of Haikou. Renowned experts and scholars from home and abroad gathered to share and exchange on the latest advancements and hot topics in the field of hematologic malignancies. At the conference, Professor DeHui Zou from the Lymphoma Diagnosis and Treatment Center of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, presented on "Progress and Considerations in CAR-T Therapy for B-Cell Lymphomas," sharing the latest research progress in the efficacy, therapeutic status, challenges faced, and optimization strategies for CAR-T treatment of Diffuse Large B-Cell Lymphoma (DLBCL). The following is a special summary.
2024 CASH丨Professor Jinghui Zhang：Monitoring clonal hematopoiesis in pediatric patients helps improve long-term prognosis

2024 CASH丨Professor Jinghui Zhang：Monitoring clonal hematopoiesis in pediatric patients helps improve long-term prognosis

2024.03.04
Clonal hematopoiesis typically refers to the proliferation of hematopoietic stem cells due to genetic mutations, which is also the basis for various hematologic diseases; monitoring clonal hematopoiesis helps in early detection of hematologic malignancies. At the Fourth China Hematology Development Conference (CASH) held recently, Professor Jinghui Zhang from St. Jude Children's Research Hospital shared a report titled "Treatment-Related Clonal Hematopoiesis in Pediatric Cancer Survivors." Following the conference, "Oncology Frontier - Hematology Frontier" invited Professor Jinghui Zhang to delve deeply into the treatment-related causes, monitoring value, and long-term effects of clonal hematopoiesis.
2024 CASH | Professor Ying Wang : Immunotherapy Brings Strong Vitality to the Treatment of Adult R/R ALL

2024 CASH | Professor Ying Wang : Immunotherapy Brings Strong Vitality to the Treatment of Adult R/R ALL

2024.03.04
The Fourth China Hematology Development Conference was held in Tianjin from January 5 to 7, 2024. Themed "Broad Hematology, Public Health, and Overall Well-being," the conference centered around the core development directions of hematology, as well as major disciplinary issues faced in basic hematology research, translation, and clinical diagnosis and treatment in the new era. It featured discussions and in-depth explorations of hot topics and frontiers, aiming to promote the construction and vigorous development of the hematology field. On this occasion, Professor Ying Wang , Director of the Comprehensive Diagnosis and Treatment Center at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, was interviewed to share the progress and breakthroughs in immunotherapy within the field of Acute Lymphoblastic Leukemia (ALL).
2024 CASH | Professor Tao Cheng: Misaligned Development, Collaborative Innovation – A Discussion on High-Quality Development in Hematology Against the Backdrop of the Innovation Era

2024 CASH | Professor Tao Cheng: Misaligned Development, Collaborative Innovation – A Discussion on High-Quality Development in Hematology Against the Backdrop of the Innovation Era

2024.03.04
The Fourth China Hematology Development Conference was held in Tianjin from January 5th to 7th, 2024. Themed "Broadening Hematology, Healthcare, and Wellness," the conference focused on the core development directions of the hematology discipline and engaged in discussions and sharing of hot topics and cutting-edge issues in basic hematology research, translation, and clinical diagnosis and treatment in the new era. During the conference, Professor Tao Cheng, the chairman of the conference and the director of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, shared the highlights of the event in an interview.
The Role of Fanconi Anemia Signaling Pathway Genes in Myelodysplastic Syndromes and Acute Myeloid Leukemia: Insights from Mutation Spectrum, Expression Profiling, and Prognosis Evaluation

The Role of Fanconi Anemia Signaling Pathway Genes in Myelodysplastic Syndromes and Acute Myeloid Leukemia: Insights from Mutation Spectrum, Expression Profiling, and Prognosis Evaluation

2024.03.01
In November 2023, a study led by Professor XiaoFan Zhu from Chinese Academy of Medical Sciences Blood Disease Hospital (Institute of Hematology, Chinese Academy of Medical Sciences) was published in the international academic journal ——BMC Med Genomics. The title of the study is "Mutation spectrum, expression profiling, and prognosis evaluation of Fanconi anemia signaling pathway genes for 4259 patients with myelodysplastic syndromes or acute myeloid leukemia". The study sheds light on the complex interplay between Fanconi anemia (FA) signaling pathway genes and the pathogenesis of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Pediatric Acute Myeloid Leukemia and Hyperleukocytosis: Prognostic Impact of High White Blood Cell Counts

Pediatric Acute Myeloid Leukemia and Hyperleukocytosis: Prognostic Impact of High White Blood Cell Counts

2024.03.01
In November 2023, a study led by Professor XiaoFan Zhu from Chinese Academy of Medical Sciences Blood Disease Hospital (Institute of Hematology, Chinese Academy of Medical Sciences) was published in the international academic journal ——Current Opinion In Pediatrics. The title of the study is "Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy". The study represents a significant prognostic challenge in pediatric AML, with recent research shedding light on its complex implications for clinical outcomes.
Iron Chelation Therapy in Myelodysplastic Syndrome Mice: A Study on Erythropoiesis and Iron Overload

Iron Chelation Therapy in Myelodysplastic Syndrome Mice: A Study on Erythropoiesis and Iron Overload

2024.03.01
In December 2023, a  study led by Professor XiaoFan Zhu from Chinese Academy of Medical Sciences Blood Disease Hospital (Institute of Hematology, Chinese Academy of Medical Sciences) was published in the international academic journal——Elife. The title of the study is "Iron chelation improves ineffective erythropoiesis and iron overload in myelodysplastic syndrome mice". The  study provides robust evidence for the effectiveness of iron chelation therapy, particularly with deferiprone (DFP), in mitigating anemia and reducing iron overload in a mouse model of myelodysplastic syndrome (MDS).